Skip to main content
. 2024 Mar 4;15:1337284. doi: 10.3389/fendo.2024.1337284

Table 1.

Baseline characteristics of training and validation cohorts.

Variable development
cohort
(n=729)
validation cohort (n=313) p-value
Male sex, n (%) 395 (54.2) 176 (56.2) 0.543
Hypertension, n (%) 360 (49.4) 144 (45.9) 0.346
Diabetes, n (%) 108 (14.8) 42 (13.4) 0.502
Hyperlipidemia, n (%) 132 (18.1) 60 (19.2) 0.685
Smoking history, n (%) 262 (35.9) 121 (38.7) 0.404
Alcohol consumption, n (%) 257 (35.3) 115 (36.7) 0.646
Age (year) 57 ± 10 56 ± 10 0.416
Heart rate (bpm) 76 ± 12 77 ± 12 0.600
SBP (mmHg) 131 ± 17 130 ± 17 0.196
DBP (mmHg) 76 ± 11 76 ± 11 0.787
Height (cm) 166.7 ± 8.1 167.0 ± 8.7 0.530
Weight (kg) 73.1 ± 13.5 73.4 ± 13.7 0.672
BMI (kg/m2) 26.2 ± 3.7 26.2 ± 3.6 0.921
LVEDD (mm) 44.65 ± 3.89 44.38 ± 3.72 0.307
LVESD (mm) 29.86 ± 3.17 29.47 ± 2.91 0.066
EF (%) 61.59 ± 4.83 62.10 ± 4.72 0.119
IVSd (mm) 10.66 ± 1.18 10.61 ± 1.17 0.544
LA-ap (mm) 34.32 ± 3.95 34.31 ± 4.01 0.957
Mitral valve E peak velocity (m/s) 0.65 ± 0.16 0.66 ± 0.16 0.607
Mitral valve A peak velocity (m/s) 0.77 ± 0.17 0.76 ± 0.18 0.467
AV-v (m/s) 1.31 ± 0.24 1.29 ± 0.25 0.231
Mitral valve E/A ratio 0.88 ± 0.28 0.90 ± 0.30 0.212
LVM (g) 236.3 ± 48.5 232.4 ± 50.3 0.239
Urea (mmol/l) 5.31 ± 1.41 5.26 ± 1.38 0.620
Creatinine (µmol/l) 73.0 ± 14.8 72.8 ± 15.5 0.896
Uric acid (µmol/l) 331.9 ± 88.9 335.8 ± 91.6 0.519
Potassium (mmol/l) 3.73 ± 0.33 3.72 ± 0.35 0.942
TC (mmol/l) 4.10 ± 0.93 4.18 ± 1.00 0.081
HDL-C (mmol/l) 1.15 ± 0.31 1.15 ± 0.31 0.905
LDL-C (mmol/l) 2.51 ± 0.82 2.61 ± 0.8 0.058
HBG (g/l) 139.2 ± 15.1 139.3 ± 15.1 0.957
WBC (10^9/L) 6.32 ± 1.60 6.24 ± 1.62 0.445
Neutrophil ratio 0.58 ± 0.90 0.57 ± 0.09 0.071
Lymphocyte ratio 0.32 ± 0.09 0.33 ± 0.08 0.067
Platelet count (10^9/L) 221.5 ± 55.8 219.0 ± 52.7 0.498
Diameters of coronary arteries
LCA (mm) 4.44 ± 0.85 4.44 ± 0.90 0.968
LAD (mm) 3.47 ± 0.67 3.45 ± 0.66 0.646
LCX (mm) 3.11 ± 0.66 3.07 ± 0.75 0.459
RAD (mm) 3.42 ± 0.72 3.38 ± 0.72 0.317
CTFC
LAD (frames) 36 ± 16 36 ± 17 0.870
LCX (frames) 29 ± 14 30 ± 15 0.239
RCA (frames) 30 ± 15 31 ± 17 0.283
ALT (U/l, Median [IQR]) 18.1 (13.5-26.2) 19.4 (13.0-28.5) 0.974
AST (U/l, Median [IQR]) 16.9 (14.2-20.5) 16.6 (14.1-22.0) 0.427
cTnT (ng/ml, Median [IQR]) 0.006
(0.004-0.008)
0.006
(0.004-0.008)
0.930
Glucose (mmol/l, Median [IQR]) 5.31 (4.82-6.02) 5.35 (4.78-5.93) 0.436
CK (U/L, Median [IQR]) 76.2 (58.9-105.8) 76.2 (55.8-102.6) 0.409
Myoglobin (U/L, Median [IQR]) 24.0 (21.0-30.3) 23.4 (21.0-30.7) 0.642
CK-MB (ng/ml, Median [IQR]) 1.18 (0.86-1.62) 1.16 (0.82-1.63) 0.493
NT-proBNP (pg/ml, Median [IQR]) 46.4 (24.4-92.7) 46.9 (24.3-90.1) 0.989
TG (mmol/l, Median [IQR]) 1.40 (1.05-1.95) 1.41 (1.06-1.95) 0.740
NLR (Median [IQR]) 1.84 (1.40-2.46) 1.78 (1.31-2.29) 0.089
SII (Median [IQR]) 387 (292-530) 382 (270-517) 0.130